<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609336</url>
  </required_header>
  <id_info>
    <org_study_id>6511</org_study_id>
    <secondary_id>NCI-2010-00553</secondary_id>
    <secondary_id>6511</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00609336</nct_id>
  </id_info>
  <brief_title>Perioperative Therapy for Resectable Pancreatic Cancer</brief_title>
  <official_title>A Phase II Study Induction Chemotherapy, Neoadjuvant Chemoradiotherapy, Surgical Resection and Adjuvant Chemotherapy for Patients With Locally Advanced, Resectable Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well giving combination chemotherapy together with&#xD;
      intensity-modulated radiation therapy (IMRT) and surgery works in treating patients with&#xD;
      localized pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such&#xD;
      as gemcitabine hydrochloride, docetaxel, capecitabine, and oxaliplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized&#xD;
      radiation therapy, such as IMRT, that delivers a high dose of radiation directly to the tumor&#xD;
      may kill more tumor cells and cause less damage to normal tissue. Giving more than one drug&#xD;
      (combination chemotherapy) together with intensity-modulated radiation therapy before surgery&#xD;
      may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.&#xD;
      Giving chemotherapy after surgery may kill any tumor cells that remain after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the median overall survival of patients with adenocarcinoma of the pancreas&#xD;
      treated with induction chemotherapy, neoadjuvant chemoradiotherapy, surgical resection and&#xD;
      adjuvant chemotherapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the percent of patients surviving at annual intervals through five years.&#xD;
&#xD;
      II. To determine the median recurrence free survival following pancreaticoduodenectomy.&#xD;
&#xD;
      III. To determine the clinical response rate to neoadjuvant chemotherapy and&#xD;
      chemoradiotherapy.&#xD;
&#xD;
      IV. To determine the pathologic response rate to neoadjuvant chemotherapy and&#xD;
      chemoradiotherapy.&#xD;
&#xD;
      V. To determine the cancer antigen (CA) 19-9 tumor marker response rate to neoadjuvant&#xD;
      chemotherapy and chemoradiotherapy.&#xD;
&#xD;
      VI. To determine the surgical completion rate and complication rate following neoadjuvant&#xD;
      chemotherapy and chemoradiotherapy.&#xD;
&#xD;
      VII. To determine the frequency and severity of toxicities associated with this treatment&#xD;
      regimen.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      INDUCTION CHEMOTHERAPY: Patients receive gemcitabine hydrochloride intravenously (IV) over 75&#xD;
      minutes and docetaxel IV over 30 or 60 minutes on days 4 and 11. Patients also receive&#xD;
      capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 21 days for&#xD;
      3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      NEOADJUVANT CHEMORADIOTHERAPY: Beginning no more than 14 days after completion of induction&#xD;
      chemotherapy, patients receive capecitabine PO BID on days 1-14 and oxaliplatin IV over 2&#xD;
      hours on days 1 and 8. Patients also undergo IMRT once daily on days 1-5 and 8-13.&#xD;
&#xD;
      SURGICAL RESECTION: Approximately 2-6 weeks after completion of neoadjuvant&#xD;
      chemoradiotherapy, patients undergo pancreaticoduodenectomy.&#xD;
&#xD;
      ADJUVANT CHEMOTHERAPY: Beginning 4-10 weeks after surgery, patients receive gemcitabine&#xD;
      hydrochloride IV over 30 minutes and oxaliplatin IV over 2 hours on day 1. Treatment repeats&#xD;
      every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients then receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15.&#xD;
      Treatment repeats every 28 days for 2 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Overall Survival of Patients With Adenocarcinoma of the Pancreas</measure>
    <time_frame>5 years</time_frame>
    <description>Time at which Kaplan-Meier estimate of overall survival drops below 50%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Surviving at 5 Years</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Kaplan-Meier estimate of overall survival at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Recurrence Free Survival Following Pancreaticoduodenectomy</measure>
    <time_frame>From the date of pancreaticoduodenectomy to date of first observation of radiographic recurrence or death due to any cause, assessed up to 7 years</time_frame>
    <description>The appearance of radiographic findings consistent with recurrent tumor at the local resection site or at a distant location is considered a radiographic recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Rate to Neoadjuvant Chemotherapy and Chemoradiotherapy</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Assessed using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic Response Rate (Complete, Near-complete, Partial) to Neoadjuvant Chemotherapy and Chemoradiotherapy</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>The resected pancreaticoduodenectomy specimen and accompanying lymph nodes will be staged according to American Joint Committee on Cancer 6th Edition incorporating the prefix y to indicate a specimen status-post neoadjuvant treatment (ypTNM). Cancer 2012;118:1382-90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA 19-9 Tumor Marker Response Rate to Neoadjuvant Chemotherapy and Chemoradiotherapy</measure>
    <time_frame>Up to 26 weeks after surgery</time_frame>
    <description>Biochemical response is a decrease of &gt;= 50% of CA 19-9 serum tumor marker in patients with elevated CA 19-9 at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Completion Rate and Complication Rate</measure>
    <time_frame>Up to 6 weeks following the completion of chemoradiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Severity of Toxicities Associated With This Treatment Regimen as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0</measure>
    <time_frame>Up to 26 weeks after surgery (the end of adjuvant chemotherapy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Surviving at Annual Intervals</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Adenocarcinoma of the Pancreas</condition>
  <condition>Stage IA Pancreatic Cancer</condition>
  <condition>Stage IB Pancreatic Cancer</condition>
  <condition>Stage IIA Pancreatic Cancer</condition>
  <condition>Stage IIB Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
    <other_name>RP 56976</other_name>
    <other_name>Taxotere</other_name>
    <other_name>TXT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
    <other_name>CAPE</other_name>
    <other_name>Ro 09-1978/000</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>L-OHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pancreatic surgical procedure</intervention_name>
    <description>Undergo pancreaticoduodenectomy</description>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
    <other_name>pancreatic surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo therapeutic conventional surgery</description>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed diagnosis of localized,&#xD;
             resectable or borderline resectable, pancreatic adenocarcinoma T1-T3, N0-N1, M0; stage&#xD;
             is determined by helical multi-phase computed tomography (CT) and/or endoscopic&#xD;
             ultrasound according to published guidelines; resectability is determined by the&#xD;
             treating surgeon and published guidelines (National Comprehensive Cancer Network)&#xD;
&#xD;
          -  Resectable Disease- Head/Body/Tail of pancreas:&#xD;
&#xD;
               -  No distant metastases&#xD;
&#xD;
               -  Clear fat plane around celiac and superior mesenteric arteries (SMA)&#xD;
&#xD;
               -  Patent superior mesenteric vein (SMV) and portal vein (PV)&#xD;
&#xD;
          -  Borderline Resectable Disease -Head/Body of pancreas:&#xD;
&#xD;
               -  Tumor abutment on SMA&#xD;
&#xD;
               -  SMV/portal vein impingement or occlusion if involving only a short segment, with&#xD;
                  open vein both proximally and distally (if proximal vein is occluded up to the&#xD;
                  portal vein branches then disease is unresectable)&#xD;
&#xD;
               -  Colon or mesocolon invasion&#xD;
&#xD;
               -  Gastroduodenal artery (GDA) encasement up to origin at hepatic artery&#xD;
&#xD;
          -  Tail of pancreas:&#xD;
&#xD;
               -  Adrenal, colon or mesocolon, or kidney invasion&#xD;
&#xD;
               -  Preoperative evidence of biopsy-positive peripancreatic lymph node&#xD;
&#xD;
          -  No prior therapy for pancreatic cancer&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 60%)&#xD;
&#xD;
          -  Leucocytes &gt;= 3,000/uL&#xD;
&#xD;
          -  Absolute Neutrophil Count &gt;= 1,500/uL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/uL&#xD;
&#xD;
          -  Total Bilirubin:&#xD;
&#xD;
               -  If within normal limits (WNL) to =&lt; 2.0, the subject is eligible&#xD;
&#xD;
               -  If &gt; 2.0 - &lt; 6.0, subject is eligible IF they have a biliary stent and total&#xD;
                  bilirubin is decreasing&#xD;
&#xD;
               -  If &gt;= 6.0, subject is not eligible&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvic transaminase [SGPT]) =&lt;&#xD;
             2.5 X institutional upper limit of normal or =&lt; 1.5 X upper limit of normal (ULN) if&#xD;
             alkaline phosphatase (Alk Phos) &gt; 2.5 X ULN or if the subject has a biliary stent and&#xD;
             the liver function tests (LFTs) are decreasing the subject is eligible&#xD;
&#xD;
          -  Creatinine clearance &gt;= 30%&#xD;
&#xD;
          -  Negative pregnancy test for women of childbearing potential; women of childbearing&#xD;
             potential and men must agree to use adequate contraception (hormonal or barrier method&#xD;
             of birth control; abstinence) prior to study entry and for the duration of study&#xD;
             participation; should a woman become pregnant or suspect she is pregnant while&#xD;
             participating in this study, she should inform her treating physician immediately&#xD;
&#xD;
          -  Ability to swallow and retain oral medication&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
          -  Histology other than adenocarcinoma&#xD;
&#xD;
          -  Patients with permanently unresectable pancreatic adenocarcinoma as determined by the&#xD;
             treating physician and published guidelines (National Comprehensive Cancer Network)&#xD;
&#xD;
          -  Unresectable disease&#xD;
&#xD;
          -  Head of pancreas:&#xD;
&#xD;
               -  Distant metastases (includes celiac and/or para-aortic)&#xD;
&#xD;
               -  SMA, celiac encasement&#xD;
&#xD;
               -  SMV/portal occlusion&#xD;
&#xD;
               -  Aortic, inferior vena cava (IVC) invasion or encasement&#xD;
&#xD;
               -  Invasion of SMV below transverse mesocolon&#xD;
&#xD;
          -  Body of pancreas:&#xD;
&#xD;
               -  Distant metastases (includes celiac and/or para-aortic); at the discretion of the&#xD;
                  treating surgeon, body and tail lesions that have positive celiac and/or&#xD;
                  para-aortic nodes in close vicinity to the primary may be borderline rather than&#xD;
                  unresectable&#xD;
&#xD;
               -  SMA, celiac, hepatic encasement&#xD;
&#xD;
               -  SMV/portal extended occlusion&#xD;
&#xD;
               -  Aortic invasion&#xD;
&#xD;
          -  Tail of pancreas:&#xD;
&#xD;
               -  Distant metastases (includes celiac and/or para-aortic)&#xD;
&#xD;
               -  SMA, celiac encasement&#xD;
&#xD;
               -  Rib, vertebral invasion&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to gemcitabine, docetaxel, capecitabine, oxaliplatin or other agents used&#xD;
             in the study&#xD;
&#xD;
          -  Patients who have received prior chemotherapy or radiotherapy for the diagnosis of&#xD;
             pancreatic cancer&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Inability to comply with study and/or follow-up procedures&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients receiving combination&#xD;
             anti-retroviral therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Coveler</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <results_first_submitted>March 21, 2017</results_first_submitted>
  <results_first_submitted_qc>June 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2017</results_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Andrew Coveler</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
          <description>See Detailed Description&#xD;
gemcitabine hydrochloride: Given IV&#xD;
docetaxel: Given IV&#xD;
capecitabine: Given PO&#xD;
intensity-modulated radiation therapy: Undergo IMRT&#xD;
oxaliplatin: Given IV&#xD;
pancreatic surgical procedure: Undergo pancreaticoduodenectomy&#xD;
therapeutic conventional surgery: Undergo therapeutic conventional surgery&#xD;
gemcitabine: Given IV&#xD;
oxaliplatin: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Surgery</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>LA or Met at Surgery</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All eligible patients</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
          <description>See Detailed Description&#xD;
gemcitabine hydrochloride: Given IV&#xD;
docetaxel: Given IV&#xD;
capecitabine: Given PO&#xD;
intensity-modulated radiation therapy: Undergo IMRT&#xD;
oxaliplatin: Given IV&#xD;
pancreatic surgical procedure: Undergo pancreaticoduodenectomy&#xD;
therapeutic conventional surgery: Undergo therapeutic conventional surgery&#xD;
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="46" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Overall Survival of Patients With Adenocarcinoma of the Pancreas</title>
        <description>Time at which Kaplan-Meier estimate of overall survival drops below 50%</description>
        <time_frame>5 years</time_frame>
        <population>All eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description&#xD;
gemcitabine hydrochloride: Given IV&#xD;
docetaxel: Given IV&#xD;
capecitabine: Given PO&#xD;
intensity-modulated radiation therapy: Undergo IMRT&#xD;
oxaliplatin: Given IV&#xD;
pancreatic surgical procedure: Undergo pancreaticoduodenectomy&#xD;
therapeutic conventional surgery: Undergo therapeutic conventional surgery&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival of Patients With Adenocarcinoma of the Pancreas</title>
          <description>Time at which Kaplan-Meier estimate of overall survival drops below 50%</description>
          <population>All eligible patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" lower_limit="14.2" upper_limit="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients Surviving at 5 Years</title>
        <description>Kaplan-Meier estimate of overall survival at 5 years</description>
        <time_frame>Up to 5 years</time_frame>
        <population>all eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description&#xD;
gemcitabine hydrochloride: Given IV&#xD;
docetaxel: Given IV&#xD;
capecitabine: Given PO&#xD;
intensity-modulated radiation therapy: Undergo IMRT&#xD;
oxaliplatin: Given IV&#xD;
pancreatic surgical procedure: Undergo pancreaticoduodenectomy&#xD;
therapeutic conventional surgery: Undergo therapeutic conventional surgery&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Surviving at 5 Years</title>
          <description>Kaplan-Meier estimate of overall survival at 5 years</description>
          <population>all eligible patients</population>
          <units>percentage of eligible pts alive</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Recurrence Free Survival Following Pancreaticoduodenectomy</title>
        <description>The appearance of radiographic findings consistent with recurrent tumor at the local resection site or at a distant location is considered a radiographic recurrence.</description>
        <time_frame>From the date of pancreaticoduodenectomy to date of first observation of radiographic recurrence or death due to any cause, assessed up to 7 years</time_frame>
        <population>Among eligible patients who received surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description&#xD;
gemcitabine hydrochloride: Given IV&#xD;
docetaxel: Given IV&#xD;
capecitabine: Given PO&#xD;
intensity-modulated radiation therapy: Undergo IMRT&#xD;
oxaliplatin: Given IV&#xD;
pancreatic surgical procedure: Undergo pancreaticoduodenectomy&#xD;
therapeutic conventional surgery: Undergo therapeutic conventional surgery&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Median Recurrence Free Survival Following Pancreaticoduodenectomy</title>
          <description>The appearance of radiographic findings consistent with recurrent tumor at the local resection site or at a distant location is considered a radiographic recurrence.</description>
          <population>Among eligible patients who received surgery</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" lower_limit="12.5" upper_limit="NA">Upper limit is infinite.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response Rate to Neoadjuvant Chemotherapy and Chemoradiotherapy</title>
        <description>Assessed using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.</description>
        <time_frame>Up to 7 years</time_frame>
        <population>Clinical response not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description&#xD;
gemcitabine hydrochloride: Given IV&#xD;
docetaxel: Given IV&#xD;
capecitabine: Given PO&#xD;
intensity-modulated radiation therapy: Undergo IMRT&#xD;
oxaliplatin: Given IV&#xD;
pancreatic surgical procedure: Undergo pancreaticoduodenectomy&#xD;
therapeutic conventional surgery: Undergo therapeutic conventional surgery&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response Rate to Neoadjuvant Chemotherapy and Chemoradiotherapy</title>
          <description>Assessed using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.</description>
          <population>Clinical response not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathologic Response Rate (Complete, Near-complete, Partial) to Neoadjuvant Chemotherapy and Chemoradiotherapy</title>
        <description>The resected pancreaticoduodenectomy specimen and accompanying lymph nodes will be staged according to American Joint Committee on Cancer 6th Edition incorporating the prefix y to indicate a specimen status-post neoadjuvant treatment (ypTNM). Cancer 2012;118:1382-90</description>
        <time_frame>Up to 7 years</time_frame>
        <population>all eligible patients with non-missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description&#xD;
gemcitabine hydrochloride: Given IV&#xD;
docetaxel: Given IV&#xD;
capecitabine: Given PO&#xD;
intensity-modulated radiation therapy: Undergo IMRT&#xD;
oxaliplatin: Given IV&#xD;
pancreatic surgical procedure: Undergo pancreaticoduodenectomy&#xD;
therapeutic conventional surgery: Undergo therapeutic conventional surgery&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Response Rate (Complete, Near-complete, Partial) to Neoadjuvant Chemotherapy and Chemoradiotherapy</title>
          <description>The resected pancreaticoduodenectomy specimen and accompanying lymph nodes will be staged according to American Joint Committee on Cancer 6th Edition incorporating the prefix y to indicate a specimen status-post neoadjuvant treatment (ypTNM). Cancer 2012;118:1382-90</description>
          <population>all eligible patients with non-missing data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CA 19-9 Tumor Marker Response Rate to Neoadjuvant Chemotherapy and Chemoradiotherapy</title>
        <description>Biochemical response is a decrease of &gt;= 50% of CA 19-9 serum tumor marker in patients with elevated CA 19-9 at baseline.</description>
        <time_frame>Up to 26 weeks after surgery</time_frame>
        <population>Biomarker data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description&#xD;
gemcitabine hydrochloride: Given IV&#xD;
docetaxel: Given IV&#xD;
capecitabine: Given PO&#xD;
intensity-modulated radiation therapy: Undergo IMRT&#xD;
oxaliplatin: Given IV&#xD;
pancreatic surgical procedure: Undergo pancreaticoduodenectomy&#xD;
therapeutic conventional surgery: Undergo therapeutic conventional surgery&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>CA 19-9 Tumor Marker Response Rate to Neoadjuvant Chemotherapy and Chemoradiotherapy</title>
          <description>Biochemical response is a decrease of &gt;= 50% of CA 19-9 serum tumor marker in patients with elevated CA 19-9 at baseline.</description>
          <population>Biomarker data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgical Completion Rate and Complication Rate</title>
        <time_frame>Up to 6 weeks following the completion of chemoradiotherapy</time_frame>
        <population>all eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description&#xD;
gemcitabine hydrochloride: Given IV&#xD;
docetaxel: Given IV&#xD;
capecitabine: Given PO&#xD;
intensity-modulated radiation therapy: Undergo IMRT&#xD;
oxaliplatin: Given IV&#xD;
pancreatic surgical procedure: Undergo pancreaticoduodenectomy&#xD;
therapeutic conventional surgery: Undergo therapeutic conventional surgery&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Surgical Completion Rate and Complication Rate</title>
          <population>all eligible patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Completion rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complication rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Severity of Toxicities Associated With This Treatment Regimen as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0</title>
        <time_frame>Up to 26 weeks after surgery (the end of adjuvant chemotherapy)</time_frame>
        <population>All eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description&#xD;
gemcitabine hydrochloride: Given IV&#xD;
docetaxel: Given IV&#xD;
capecitabine: Given PO&#xD;
intensity-modulated radiation therapy: Undergo IMRT&#xD;
oxaliplatin: Given IV&#xD;
pancreatic surgical procedure: Undergo pancreaticoduodenectomy&#xD;
therapeutic conventional surgery: Undergo therapeutic conventional surgery&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Severity of Toxicities Associated With This Treatment Regimen as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0</title>
          <population>All eligible patients</population>
          <units>occurrence of toxicities</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Grade 2 CTCAE toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Grade 3 CTCAE toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Grade 4 CTCAE toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients Surviving at Annual Intervals</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description&#xD;
gemcitabine hydrochloride: Given IV&#xD;
docetaxel: Given IV&#xD;
capecitabine: Given PO&#xD;
intensity-modulated radiation therapy: Undergo IMRT&#xD;
oxaliplatin: Given IV&#xD;
pancreatic surgical procedure: Undergo pancreaticoduodenectomy&#xD;
therapeutic conventional surgery: Undergo therapeutic conventional surgery&#xD;
gemcitabine: Given IV&#xD;
oxaliplatin: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Surviving at Annual Intervals</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
          <description>See Detailed Description&#xD;
gemcitabine hydrochloride: Given IV&#xD;
docetaxel: Given IV&#xD;
capecitabine: Given PO&#xD;
intensity-modulated radiation therapy: Undergo IMRT&#xD;
oxaliplatin: Given IV&#xD;
pancreatic surgical procedure: Undergo pancreaticoduodenectomy&#xD;
therapeutic conventional surgery: Undergo therapeutic conventional surgery&#xD;
gemcitabine: Given IV&#xD;
oxaliplatin: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fever, Neutropenic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="24" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Thrombotic Microangiopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attacks</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Entero Cutaneous Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Lower GI Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Shoulder Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cholangitis With Stent Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cholecystic Abcess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Intrahepatic Absesses</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Non-Malignant Ascitess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Obstructive Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Portal Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bacterial Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypoatremic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nose Bleeds</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-foot Syndrome</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Anasarca</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Transaminase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Maculopapular Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand Foot Syndrome</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Maculopapular Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rash - Upper Torso</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Coveler, MD</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-288-7509</phone>
      <email>acoveler@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

